☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Innovent Biologics
Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis
October 17, 2024
The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC
August 22, 2024
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
May 9, 2024
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)
May 7, 2024
Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease
February 20, 2024
Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tu...
December 28, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.